Cytosorbents (NASDAQ:CTSO) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Cytosorbents (NASDAQ:CTSO) posted its quarterly earnings results on Thursday. The medical research company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.02, FiscalAI reports. Cytosorbents had a negative return on equity of 111.97% and a negative net margin of 25.58%.

Cytosorbents Price Performance

NASDAQ:CTSO traded up $0.03 during midday trading on Thursday, hitting $0.67. 285,132 shares of the stock were exchanged, compared to its average volume of 164,609. The business has a 50-day moving average price of $0.88 and a two-hundred day moving average price of $0.96. The company has a current ratio of 2.34, a quick ratio of 1.96 and a debt-to-equity ratio of 1.24. The company has a market capitalization of $41.77 million, a price-to-earnings ratio of -3.91 and a beta of 1.28. Cytosorbents has a one year low of $0.61 and a one year high of $1.61.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. D. Boral Capital reiterated a “buy” rating and set a $10.00 target price on shares of Cytosorbents in a research note on Tuesday, September 16th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cytosorbents in a report on Tuesday, October 14th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.50.

Institutional Investors Weigh In On Cytosorbents

A hedge fund recently raised its stake in Cytosorbents stock. Goldman Sachs Group Inc. boosted its holdings in shares of Cytosorbents Corporation (NASDAQ:CTSO) by 149.2% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 62,662 shares of the medical research company’s stock after purchasing an additional 37,519 shares during the period. Goldman Sachs Group Inc. owned approximately 0.10% of Cytosorbents worth $63,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.